These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8789386)

  • 1. Structure activity studies of mast cell activation and hypotension induced by neuropeptide Y (NPY), centrally truncated and C-terminal NPY analogues.
    Cross LJ; Beck-Sickinger AG; Bienert M; Gaida W; Jung G; Krause E; Ennis M
    Br J Pharmacol; 1996 Jan; 117(2):325-32. PubMed ID: 8789386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropeptide Y, peptide YY and C-terminal fragments release histamine from rat peritoneal mast cells.
    Grundemar L; Håkanson R
    Br J Pharmacol; 1991 Dec; 104(4):776-8. PubMed ID: 1725763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-terminal neuropeptide Y fragments are mast cell-dependent vasodepressor agents.
    Shen GH; Grundemar L; Zukowska-Grojec Z; Håkanson R; Wahlestedt C
    Eur J Pharmacol; 1991 Nov; 204(3):249-56. PubMed ID: 1723049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropeptide Y and truncated neuropeptide Y analogs evoke histamine release from rat peritoneal mast cells. A direct effect on G proteins?
    Grundemar L; Krstenansky JL; Håkanson R
    Eur J Pharmacol; 1994 Jun; 258(1-2):163-6. PubMed ID: 7523149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural requirements for neuropeptide Y in mast cell and G protein activation.
    Mousli M; Trifilieff A; Pelton JT; Gies JP; Landry Y
    Eur J Pharmacol; 1995 Mar; 289(1):125-33. PubMed ID: 7540143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural requirements for neuropeptide Y18-36-evoked hypotension: a systematic study.
    Feinstein RD; Boublik JH; Kirby D; Spicer MA; Craig AG; Malewicz K; Scott NA; Brown MR; Rivier JE
    J Med Chem; 1992 Jul; 35(15):2836-43. PubMed ID: 1379641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of positive charges of neuropeptide Y fragments in mast cell activation.
    Mousli M; Landry Y
    Agents Actions; 1994 Jun; 41 Spec No():C41-2. PubMed ID: 7526655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of centrally truncated analogues of neuropeptide Y at Y1 and Y2 receptor subtypes in vivo.
    McCloskey MJ; Moriarty MJ; Tseng A; Shine J; Potter EK
    Neuropeptides; 1997 Apr; 31(2):193-7. PubMed ID: 9179873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of alpha-helicity, amphipathicity and D-amino acid incorporation on the peptide-induced mast cell activation.
    Cross LJ; Ennis M; Krause E; Dathe M; Lorenz D; Krause G; Beyermann M; Bienert M
    Eur J Pharmacol; 1995 Nov; 291(3):291-300. PubMed ID: 8719413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-helical small molecular size analogues of neuropeptide Y: structure-activity relationships.
    Jung G; Beck-Sickinger AG; Dürr H; Gaida W; Schnorrenberg G
    Biopolymers; 1991 May; 31(6):613-9. PubMed ID: 1657233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Truncated, branched, and/or cyclic analogues of neuropeptide Y: importance of the pancreatic peptide fold in the design of specific Y2 receptor ligands.
    Reymond MT; Delmas L; Koerber SC; Brown MR; Rivier JE
    J Med Chem; 1992 Oct; 35(20):3653-9. PubMed ID: 1433176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropeptide Y(5) receptors reduce synaptic excitation in proximal subiculum, but not epileptiform activity in rat hippocampal slices.
    Ho MW; Beck-Sickinger AG; Colmers WF
    J Neurophysiol; 2000 Feb; 83(2):723-34. PubMed ID: 10669488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and hypertensive activity of neuropeptide Y fragments and analogues with modified N- or C-termini or D-substitutions.
    Boublik JH; Scott NA; Brown MR; Rivier JE
    J Med Chem; 1989 Mar; 32(3):597-601. PubMed ID: 2918505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Y3 receptor-mediated synaptic inhibition by chimeric neuropeptide Y-peptide YY peptides in the rat brainstem.
    Glaum SR; Miller RJ; Rhim H; Maclean D; Georgic LM; MacKenzie RG; Grundemar L
    Br J Pharmacol; 1997 Feb; 120(3):481-7. PubMed ID: 9031753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human and rat cutaneous mast cells: involvement of a G protein in the response to peptidergic stimuli.
    Emadi-Khiav B; Mousli M; Bronner C; Landry Y
    Eur J Pharmacol; 1995 Jan; 272(1):97-102. PubMed ID: 7536161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasoconstrictor effects of various neuropeptide Y analogues on the rat tail artery in the presence of phenylephrine.
    Tschöpl M; Miller RC; Pelton J; Stoclet JC; Bucher B
    Br J Pharmacol; 1993 Nov; 110(3):1098-104. PubMed ID: 8298798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropeptide Y-induced mast cell activation.
    Cross LJ; Beck-Sickinger AG; Beyerman M; Krause E; Bienert M; Ennis M
    Biochem Soc Trans; 1994 Feb; 22(1):7S. PubMed ID: 7515834
    [No Abstract]   [Full Text] [Related]  

  • 18. Modulation by neuropeptide Y of parasympathetic nerve-evoked nasal vasodilatation via Y2 prejunctional receptor.
    Lacroix JS; Ulman LG; Potter EK
    Br J Pharmacol; 1994 Oct; 113(2):479-84. PubMed ID: 7834199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropeptide Y modulates effects of bradykinin and prostaglandin E2 on trigeminal nociceptors via activation of the Y1 and Y2 receptors.
    Gibbs JL; Diogenes A; Hargreaves KM
    Br J Pharmacol; 2007 Jan; 150(1):72-9. PubMed ID: 17143304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.
    Doods HN; Wienen W; Entzeroth M; Rudolf K; Eberlein W; Engel W; Wieland HA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):136-42. PubMed ID: 7562541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.